Indikator likuiditas cepet Nasus Pharma Ltd (NSRX)

This price chart for Nasus Pharma Ltd (NSRX) allows for an assessment of how an innovative environment and a lack of bureaucracy impact capitalization, which currently stands at 8.81. The business generates revenue by creating nasal barrier sprays against allergies and viruses. The startup is currently scaling emergency drug delivery systems, aiming for licensing deals with pharmaceutical behemoths following the completion of trials.

This indicator assesses a company's ability to instantaneously settle short-term obligations using only cash and accounts receivable, excluding slow-moving inventories. An analysis of the quick ratio, combined with the high utilization of automated lines at Nasus Pharma Ltd (NSRX), confirms the business's financial autonomy, ensuring capital protection against crisis-driven drawdowns while maintaining operational efficiency.